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Abstract—We investigated the associations of pulse pressure (a measure of arterial stiffness) with the early glycation products
hemoglobin A1c (HbA1c) and Amadori albumin and the advanced glycation end products pentosidine, N-
(carboxymethyl)lysine and N-(carboxyethyl)lysine in a large group of type 1 diabetic individuals of the EURODIAB
Prospective Complications Study. We did a cross-sectional nested case-control study from the EURODIAB Prospective
Complications Study of 543 (278 men) European individuals with type 1 diabetes diagnosed at 36 years of age. We used
linear regression analyses to investigate the association of pulse pressure with glycation products. Pulse pressure was
significantly associated with plasma levels of N-(carboxymethyl)lysine and N-(carboxyethyl)lysine but not with HbA1c,
Amadori albumin, and urinary levels of pentosidine. Regression coefficients adjusted for age, sex, mean arterial pressure, and
duration of diabetes were 0.09 mm Hg (P0.003) per 1 M/M lysine N-(carboxymethyl)lysine; 0.24 mm Hg (P0.001) and
0.03 mm Hg (P0.62) per 1 M/M lysine N-(carboxyethyl)lysine (in individuals with and without complications,
respectively; P interaction0.002); and 0.50 mm Hg (P0.16) per 1% HbA1c; 0.07 mm Hg (P0.12) per 1 U/mL Amadori
albumin; and 0.77 mm Hg (P0.48) per 1 nmol/mmol creatinine pentosidine. In young type 1 diabetic individuals, arterial
stiffness is strongly associated with the advanced glycation end products N-(carboxymethyl)lysine and N-
(carboxyethyl)lysine. These findings suggest that the formation of advanced glycation end products is an important pathway
in the development of arterial stiffness in young type 1 diabetic individuals. (Hypertension. 2005;46:232-237.)
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Increased arterial stiffness is associated with increasedcardiovascular risk1 because it increases myocardial after-
load and oxygen demand, leads to left ventricular hypertro-
phy, and limits coronary filling during diastole.2 Recent
studies have shown that arterial aging in type 1 and type 2
diabetes is accelerated.3,4 However, the exact mechanisms
that are involved in accelerated stiffening of arteries remain
unknown. One of the main mechanisms thought to be
involved is the formation of advanced glycation end products
(AGEs), especially in diabetic individuals. AGEs that form
on the arterial wall can cause cross-linking of collagen
molecules, which may lead to loss of collagen elasticity and
a subsequent reduction in arterial elasticity.5 Recently, cross-
link breakers have been demonstrated to decrease arterial
stiffness in humans, providing additional evidence for the
importance of AGE formation in arterial stiffening.6
Studies on arterial stiffness have been performed in elderly
or type 2 diabetic individuals because arterial stiffness,
specifically pulse pressure, tends to increase at 50 years of
age.7,8 However, in type 1 diabetes, pulse pressure increases
even at an earlier age.3 In contrast to mean arterial pressure,
which represents the steady component of the propagation of
the pressure wave through the arterial system, pulse pressure
represents the pulsatile component of circulatory stress.
Arterial pulse pressure is determined by cardiac output and
arterial stiffness.9 Variability in pulse pressure is thought to
be caused, to a large extent, by variability in arterial stiffness.
The influence of AGE formation on arterial stiffness in young
type 1 diabetic individuals has not been investigated previously.
Therefore, we investigated the associations of the early glycation
products hemoglobin A1c (HbA1c) and Amadori albumin and
the AGEs pentosidine, N-(carboxymethyl)lysine (CML), and
N-(carboxyethyl)lysine (CEL) with pulse pressure as a measure
of arterial stiffness in a large group of type 1 diabetic individuals
of the EURODIAB Prospective Complications Study.
Methods
Study Population
Full details of the design, methods, and recruitment in the EURO-
DIAB Prospective Complications Study have been published previ-
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ously.10 The EURODIAB Prospective Complications Study is a
follow-up of the EURODIAB IDDM (insulin-dependent diabetes
mellitus) Complications Study.11 Baseline investigations (1988 to
1991) were performed on 3250 men and women with type 1 diabetes
drawn from 31 European centers. All subjects gave informed
consent, and the study was approved by local ethics committees.
Sample selection was stratified by sex, age group, and duration of
diabetes to ensure sufficient representation in all categories. Type 1
diabetes was clinically defined as a diagnosis made at 36 years of
age, with a continuous need for insulin therapy within 1 year of
diagnosis. The follow-up was performed on average 7 to 9 years
later. Of the 3250 patients, 1880 (57.8%) returned for examina-
tion.10,12,13 At follow-up, a cross-sectional nested case-control study
on AGEs was performed (n543). Data presented here were based
on these cross-sectional data. AGEs could not be determined at
baseline because these samples have run out.
We assessed microvascular complications and cardiovascular
disease, did a physical examination, measured height, weight, waist
and hip circumference, and resting blood pressure, obtained infor-
mation on smoking habits, and measured biochemical variables
according to a standardized protocol.11 Albumin excretion rates were
measured from 224-hour urine collections at a single center as
described previously.10 Microalbuminaria and macroalbuminuria
were defined as albumin excretion rates of between 20 and 200 g
per minute and 200 g per minute, respectively. We estimated
glomerular filtration rate (GFR) by the Cockcroft–Gault formula.
Retinopathy was assessed from retinal photographs according to the
EURODIAB protocol.14 Cardiovascular disease was defined as a
positive medical history of a cardiovascular event, including myo-
cardial infarction, angina, coronary artery bypass graft or stroke, or
ischemic changes on a Minnesota-coded ECG.15
Blood pressure was measured by a random-zero sphygmomanom-
eter (Hawskley). With an appropriately sized cuff, 2 blood pressure
readings were taken from the right arm with the patient in a seated
position after resting for 5 minutes. Readings were taken from the
top of the meniscus, and measurement was recorded to the nearest
2 mm Hg. Diastolic pressure was recorded at the disappearance of
sound (Korotkoff phase V). Data presented here are based on the
mean of 2 measurements. Mean arterial pressure was defined as two
thirds of diastolic plus one third of systolic pressure and pulse
pressure as systolic minus diastolic pressure. Hypertension was
defined as a systolic pressure of 140 mm Hg, a diastolic pressure
of 90 mm Hg, or the current use of blood pressure–lowering drugs.
Laboratory Measurements
HbA1c was measured by an enzyme immunoassay using a mono-
clonal antibody against HbA1c (DAKO; n535).16 Amadori albu-
min was determined in a competitive ELISA as described previously
(n535).17 Pentosidine levels were determined in unhydrolyzed
urine as described previously (n536).18 Urinary excretion of
pentosidine was normalized for urine concentration by expressing it
as nmol pentosidine/mmol urinary creatinine. CML and CEL were
determined in plasma as described previously19 with an interassay
coefficient of variation of 6.0% (n536 and n535, respectively).
CML and CEL were normalized for lysine concentration by express-
ing it as M/M lysine. Fasting follow-up blood samples were sent to
central laboratories for analyses of lipid profile.15
Statistical Analysis
Because this study was designed to study determinants of diabetic
complications, we used a nested case-control approach to compare
individuals with and without complications. Cases were selected to
have the greatest complication burden as possible to provide suffi-
cient numbers for subgroup analyses. Controls were selected to be
completely free of complications (including neuropathy). Thus, cases
were all those with cardiovascular disease or proliferative retinopa-
thy or macroalbuminuria at follow-up and all those with microalbu-
minuria and some degree of retinopathy (n348). Controls were all
those who had no evidence of cardiovascular disease, retinopathy, or
neuropathy, and were normoalbuminuric at follow-up (n195).
Cases and controls were unmatched so that the impact of key
variables, such as age, could still be assessed, and any adjustments
were taken care of at the analysis stage.
All analyses were performed with SPSS 11.5 for Windows. We
focused on the cross-sectional associations of pulse pressure, systolic
pressure, and diastolic pressure with HbA1c, Amadori albumin,
pentosidine, CML, and CEL by use of linear regression analyses. We
initially performed these analyses stratified by the presence or
absence of complications. Then we investigated, by use of interac-
tion terms of glycation products with the presence of complications,
whether findings across strata were significantly different. Because
findings were similar across strata, except those involving CEL, we
combined the groups, except in analyses involving CEL.
P values 0.05 were considered statistically significant, except
for interaction terms, where P values 0.10 were considered
statistically significant.
Results
Table 1 shows the characteristics of the study population per
tertile of pulse pressure. As anticipated, cardiovascular risk
factor status was worst in the highest tertile of pulse pressure.
However, HbA1c levels did not differ by tertile of pulse
pressure. Amadori albumin, CEL, and pentosidine were
significantly and positively related to pulse pressure. The
association with CML was borderline significant (P0.06).
Table 2 shows the associations of pulse pressure, systolic
pressure and diastolic pressure with HbA1c and Amadori albu-
min. Pulse pressure, systolic pressure, and diastolic pressure
levels were not associated with HbA1c. Pulse pressure and
systolic pressure were associated with Amadori albumin; how-
ever, this association disappeared after adjustments for age, sex,
mean arterial pressure, and duration of diabetes (model 1).
Table 3 shows the associations of pulse pressure, systolic
pressure, and diastolic pressure with AGEs. Pulse pressure
and systolic pressure were associated with pentosidine and
CML in crude analyses. In adjusted analyses, the associations
with CML remained present, whereas the association with
pentosidine disappeared. Diastolic pressure was associated
inversely with CML in adjusted analyses. The associations of
pulse pressure, systolic pressure, and diastolic pressure with
CEL were significantly stronger in individuals with compli-
cations compared with those without complications (Table 3;
interaction analyses). Therefore, analyses were stratified for
complication status. Pulse pressure and systolic pressure were
strongly associated with CEL in individuals with complica-
tions in crude and adjusted analyses (Table 3). Diastolic
pressure was inversely associated with CEL in individuals
with complications in adjusted analyses. Measures of blood
pressure were not associated with CEL in individuals without
complications. The interaction of CEL with complications in
the association of pulse pressure with CEL indicates that this
association is stronger in the presence of complications.
Additional Adjustments
Additional adjustments for GFR, body mass index, waist-to-
hip ratio, lipid profile, HbA1c (when this was not the
dependent variable), the presence of retinopathy, microalbu-
minaria or macroalbuminuria, or cardiovascular disease, and
the use of antihypertensive or lipid-lowering drugs did not
materially change the results presented in Tables 2 and 3.
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Discussion
The main outcome of this study is that pulse pressure, an
estimate of arterial stiffness, was strongly and independently
associated with the AGEs, CML, and CEL in young type 1
diabetic individuals. This is the first study to demonstrate that
AGEs are associated with arterial stiffness in relatively young
type 1 diabetic individuals. This interpretation is strengthened
by the finding that CML and CEL were directly associated
with systolic pressure and inversely with diastolic pressure,
because greater arterial stiffness will increase systolic and
decrease diastolic pressure. In addition, these associations
were independent of mean arterial pressure (ie, the static
blood pressure factor).
The association of pulse pressure with CEL was signifi-
cantly stronger in type 1 diabetic individuals with complica-
tions compared with individuals without complications,
which may indicate that type 1 diabetic individuals with
complications may be especially vulnerable to the arterial
stiffness–increasing effects of CEL. In contrast, pulse pres-
sure was not independently associated with the early glyca-
tion products HbA1c and Amadori albumin and the AGE
pentosidine.
CML and CEL are noncross-linking AGEs, yet were
strongly associated with pulse pressure. AGEs are formed by
a nonenzymatic reaction between reducing sugars and pro-
teins. These stable compounds accumulate slowly throughout
the life span and are thought to contribute to age- and
diabetes-associated structural changes in the cardiovascular
system, such as increased vascular stiffness.5 The mecha-
nisms underlying this AGE-induced effect on vascular stiff-
ness include the formation of collagen cross-linking that
alters the structure and function of the extracellular matrix.5
However, the introduction of CML or CEL moieties on
proteins may affect the properties of the modified proteins but
does not cause cross-linking in or between proteins.20,21
Therefore, our findings strongly suggest that the effect of
CML and CEL on arterial stiffness involves other mecha-
nisms than cross-linking, such as ligation of the receptor for
TABLE 1. Characteristics of 543 Type 1 Diabetic Patients per Tertiles of Pulse Pressure
Variable
First Tertile of
Pulse Pressure
(17–39.5 mm Hg)
Second Tertile of
Pulse Pressure
(40–51 mm Hg)
Third Tertile of
Pulse Pressure
(51.5–129 mm Hg)
P Value
for Trend
Clinical characteristics
Sex, men/women 85/95 103/80 90/90 0.2
Age, years 34.97.9 38.78.8 45.610.5 0.001
Duration of type 1 diabetes, years 15.6 (10.9–21.8) 20.0 (14.4–25.6) 26.7 (19.5–32.9) 0.001
Body mass index, kg/m2 23.92.8 24.33.1 25.33.7 0.001
Waist-to-hip ratio 0.880.15 0.890.14 0.890.13 0.7
Smoking status, never/past/current, % 47/22/31 35/30/35 39/36/25 0.1
Complications
No/background/proliferative retinopathy, % 59/24/17 49/26/26 24/33/43 0.001
Normoalbuminuria/microalbuminaria/macroalbuminuria, % 75/13/12 63/16/21 44/17/39 0.001
GFR, mL/min per 1.73 m2 110.421.8 104.723.6 94.328.3 0.001
Cardiovascular disease (n489), % 19 29 35 0.001
Blood pressures
Systolic and diastolic blood pressure, mm Hg 10811/7510 12012/7511 14218/7613 0.001/0.5
Mean arterial pressure, mm Hg 8610 9011 9813 0.001
Pulse pressure, mm Hg 335 454 6615 —
Hypertension, % 25 29 72 0.001
Use of antihypertensive drugs, % 17 25 53 0.001
Lipid profile
Total cholesterol, mmol/L 5.021.10 5.281.02 5.611.34 0.001
HDL cholesterol, mmol/L 1.640.43 1.640.40 1.610.47 0.7
LDL cholesterol, mmol/L 2.880.89 3.130.97 3.361.24 0.001
Triglycerides, mmol/L 0.93 (0.71–1.27) 0.95 (0.74–1.36) 1.14 (0.86–1.68) 0.001
Glycation products
HbA1c, % 8.51.6 8.41.5 8.71.7 0.2
Amadori albumin, U/mL 44.815.0 44.211.1 47.913.6 0.02
CML, M/M lysine 5515 5617 5921 0.06
CEL, M/M lysine 2911 3010 3313 0.01
Pentosidine, nmol/mmol creatinine 0.44 (0.32–0.60) 0.44 (0.32–0.64) 0.48 (0.35–0.71) 0.04
Data are presented as No., percentage, or meanSD, except for duration, triglycerides, and pentosidine, which are shown as median (interquartile
range).
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AGE (RAGE). RAGE is highly expressed in the endothelium
of activated vessels.22 Recent findings demonstrated that
CML is a ligand for RAGE.23 Binding of circulating CML-
modified proteins to RAGE leads to activation of
extracellular-regulated kinase 1/2 (ERK1/2), activation of
nuclear factor B, secretion of proinflammatory cytokines,
and modulation of gene expression in several cell types, such
as monocytes, endothelial cells, and vascular smooth muscle
cells.24 This may lead to changes in the production of
extracellular matrix proteins, such as collagen and elastin
structure, and alterations in vascular elasticity.
In contrast to CML and CEL, the cross-linking AGE
pentosidine was not associated with pulse pressure. Although
the lack of an association of pulse pressure with pentosidine
may suggest that cross-linking AGEs are not important in the
development of increased arterial stiffness, the findings that
AGE–cross-link breakers, such as ALT-711, are able to
decrease arterial and myocardial stiffness5,6 suggests that
cross-linking by AGEs is important in this process. We do not
have a clear explanation why we did not find such an
association in this study. However, we measured pentosidine
in its free form in urine, which may be a poor reflection of
AGE-induced cross-linking in the vascular wall.
We cannot establish whether CML and CEL are involved
in arterial stiffness or rather serve as markers of the process
of AGE formation. However, the finding that the AGE
pentosidine was not associated with pulse pressure argues
against the latter idea. Because CML and CEL can be formed
by glycoxidation and by oxidation alone, whereas pentosidine
is a specific marker of glycoxidation,25,26 the association of
arterial stiffness with CML and CEL may reflect the involve-
ment of increased oxidative stress in arterial stiffening,
whereas glycoxidation, per se, may be less important.
In contrast to CML, which can be formed by multiple
pathways such as via glyoxal, myeloperoxidase, or the
peroxidation pathway, the primary pathway of CEL forma-
tion is during the reaction of methylglyoxal with lysine
residues. Therefore, CEL is a specific indicator of methylg-
lyoxal, whereas CML is not. Methylglyoxal has been dem-
onstrated to be the most important precursor in the formation
of AGEs.27 The interaction of CEL with complications in the
association between arterial stiffness and CEL may be ex-
plained by an increase in methylglyoxal in the presence of
diabetic complications. Indeed, increased concentration of
methylglyoxal has been linked directly to vascular complica-
tions,28 although the mechanisms and the particular methyl-
glyoxal adducts involved herein are unknown. Whether
methylglyoxal-modified proteins are also ligands for AGE
receptors is unknown, although the effects of high concentra-
tions of methylglyoxal on cultured human endothelial cells on
tyrosine phosphorylation, the phosporylation of ERK1/2, c-JUN,
and p38 mitogen-activated protein kinase, and the induction of
apoptosis29 suggest the involvement of a cellular receptor.
Pulse pressure was not associated with the early glycation
products HbA1c and Amadori albumin. These early glycation
products are highly reversible and are therefore thought to be
relatively unimportant with respect to arterial stiffening.
Although we found a significant association of pulse
pressure with CML and CEL, we cannot establish that these
AGEs play a causal role in the development of increased
arterial stiffness because of the cross-sectional setting of this
study. However, a large body of evidence supports an
important role for AGEs in the pathogenesis of diabetes-
related vascular damage. In addition, CML depositions were
specifically found in the arterial wall.30 The finding that
collagen cross-link breakers can improve arterial compliance
provides additional evidence for the importance of AGE
cross-linking in arterial stiffening.6
In summary, this study demonstrates an association of
arterial stiffness with the AGEs CML and CEL but not with
Hba1c, Amadori albumin, and pentosidine. These results
suggest that AGEs are an important pathway in the develop-
ment of arterial stiffness even in quite young type 1 diabetic
individuals.
Perspectives
We have shown previously that pulse pressure shows a steep
increase with age in young individuals with type 1 diabetes
(mean age 33 years), that this association is stronger in
individuals with (micro)albuminuria than in those with nor-
moalbuminuria, and that pulse pressure is positively associ-
ated with risk of incident cardiovascular disease.3 Our present
data suggest that the formation of AGEs is an important
pathway in the development of arterial stiffness in young type
1 diabetic individuals. A crucial next step is to investigate
whether AGEs are causally related to arterial stiffness and
TABLE 2. Cross-Sectional Associations of Pulse Pressure, Systolic Pressure, and Diastolic Pressure With
HbA1c and Amadori Albumin
Early Glycation Products
Pulse Pressure, mm Hg Systolic Pressure, mm Hg Diastolic Pressure, mm Hg
 SE P Value  SE P Value  SE P Value
HbA1c, %
Crude 0.85 0.45 0.06 0.96 0.54 0.08 0.11 0.31 0.73
Model 1 0.50 0.36 0.16 0.33 0.24 0.16 0.17 0.12 0.16
Amadori albumin, U/mL
Crude 0.16 0.05 0.003 0.14 0.07 0.03 0.02 0.04 0.66
Model 1 0.07 0.04 0.12 0.05 0.03 0.12 0.02 0.01 0.12
Model 1 was adjusted for age, sex, mean arterial pressure, and duration of diabetes. A regression coefficient () of 0.85 (top left)
indicates that per 1% increase in HbA1c, pulse pressure increases with 0.85 mm Hg.
SE indicates SE of the regression coefficient.
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cardiovascular disease in a longitudinal setting. If so, AGE-
breaking agents may be used in clinical practice for cardio-
vascular risk reduction in type 1 diabetes.
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TABLE 3. Cross-Sectional Associations of Pulse Pressure, Systolic Pressure and Diastolic Pressure With
Pentosidine, CML, and CEL
Advanced Glycation Products
Pulse Pressure, mm Hg Systolic Pressure, mm Hg Diastolic Pressure, mm Hg
 SE P Value  SE P Value  SE P Value
Pentosidine, nmol/mmol creatinine
Crude 5.37 1.32 0.001 4.77 1.61 0.001 0.60 0.92 0.52
Model 1 0.77 1.11 0.48 0.52 0.74 0.48 0.26 0.37 0.48
CML, M/M lysine
Crude 0.16 0.04 0.001 0.19 0.05 0.001 0.03 0.03 0.26
Model 1 0.09 0.03 0.003 0.06 0.02 0.003 0.03 0.01 0.003
CEL, M/M lysine
Individuals with complications
Crude 0.48 0.08 0.001 0.59 0.10 0.001 0.11 0.06 0.056
Model 1 0.24 0.07 0.001 0.16 0.05 0.001 0.08 0.02 0.001
Individuals without complications
Crude 0.01 0.07 0.87 0.07 0.09 0.44 0.06 0.07 0.42
Model 1 0.03 0.06 0.62 0.02 0.04 0.62 0.01 0.02 0.62
Interaction analyses adjusted for model 1
Intercept 15.19 5.54 0.006 10.13 3.70 0.01 5.06 1.85 0.01
CEL, per M/M lysine 0.05 0.08 0.571 0.03 0.06 0.57 0.02 0.03 0.57
Age, per year 0.37 0.07 0.001 0.25 0.05 0.001 0.12 0.03 0.001
Sex, male 1, female 2 1.68 1.13 0.138 1.12 0.75 0.14 0.56 0.38 0.14
Mean arterial pressure, per mm Hg 0.41 0.05 0.001 1.27 0.03 0.001 0.87 0.02 0.001
Duration of diabetes, per year 0.43 0.09 0.001 0.29 0.06 0.001 0.15 0.03 0.001
Presence of complications, no 0, yes 1 7.51 3.46 0.030 5.01 2.31 0.03 2.50 1.15 0.03
CELpresence of complications 0.32 0.11 0.002 0.21 0.07 0.002 0.11 0.04 0.002
Model 1 was adjusted for age, sex, mean arterial pressure, and duration of diabetes. A regression coefficient () of 5.37 (top left)
indicates that per 1 nmol/mmol creatinine increase in pentosidine pulse pressure increases with 5.37 mm Hg.
SE indicates SE of the regression coefficient.
Pentosidine was ln-transformed due to a skewed distribution.
The complete interaction model can be used to calculate the expected change in pulse pressure when CEL increases. For example, in
a man aged 35 years with a mean arterial pressure of 90 mm Hg, diabetes duration of 20 years, with complications, pulse pressure is
expected to increase by 2.7 mm Hg per 10 M/M lysine increase in CEL, whereas in a similar person without complications, pulse pressure
is expected to change with0.5 mm Hg (calculated as pulse pressure15.19(0.05CEL)(0.37age)(1.68sex)(0.41mean
arterial pressure)(0.43duration of diabetes)(7.51presence of complications)(0.32CELpresence of complications). Note that
the effect of CEL and complications on systolic pressure and diastolic pressure can be calculated in a manner analogous to that shown for
pulse pressure.
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